iron fumarate

PreclinicalSmall molecule

RRennes University Hospital

iron fumarate is one of 3 small molecule programs targeting Haemochromatosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HaemochromatosisCompleted

HaemochromatosisPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Haemochromatosis

#DrugCompanyPhaseTrials

Pregnancy Test

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 2

Urinary Pregnancy Test

RRennes University Hospital

Preclinical

1 3

iron fumarate

RRennes University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Haemochromatosis1 trial

Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis

Completed·RRennes University Hospital·N/A·NCT02099214·66 enrolled

Diagnosis1 trial

Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.

Completed·RRennes University Hospital·Phase 2·NCT01949467·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for iron fumarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iron fumarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iron fumarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rennes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRennes University Hospital

iron fumarate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Haemochromatosis1 trial

Diagnosis1 trial

References

Drug Info

Quick Facts

Related News